Berlin - Delayed Quote EUR

Johnson & Johnson (JNJ.BE)

135.74

+0.54

+(0.40%)

As of 8:08:24 AM GMT+2. Market Open.

Johnson & Johnson (NYSE:JNJ) Unveils Promising Prostate Cancer Data With Pasritamig

Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced prostate cancer, which may have influenced its stock's 1.5% rise last week. The study highlights, including a favorable safety profile and potential efficacy in disease control, likely garnered positive investor sentiment. Nevertheless, the company's stock movement is congruent with broader market trends, as the market climbed 1.7% over the same period, likely...

Simply Wall St. 1 hour ago

JNJ
ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug

The trial enrolled 174 subjects aged 36–89 years who had undergone an average of four previous therapies.

Clinical Trials Arena 4 hours ago

JNJ
COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?

Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?

Zacks 6 hours ago

COO

JNJ
HistoSonics’ histotripsy system receives early market access authorisation in UK

The authorisation for the histotripsy system was granted under the UK’s Innovative Devices Access Pathway (IDAP).

Medical Device Network 4 days ago

JNJ
3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Row

Federal Realty has increased its dividend by a REIT-leading 57 straight years. Johnson & Johnson has hiked its dividend for 63 years in a row. PepsiCo recently extended its dividend growth streak to 53 consecutive years.

Motley Fool 4 days ago

JNJ

PEP

FRT
Johnson & Johnson (JNJ) Stock Moves -0.54%: What You Should Know

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.43, denoting a -0.54% change from the preceding trading day.

Zacks 4 days ago

JNJ

^GSPC
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

NEW BRUNSWICK, N.J., May 28, 2025--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s exe

Business Wire 4 days ago

JNJ
Boston Scientific ends TAVR sales; J&J shares Monarch robot data

Boston Scientific said it would halt worldwide sales of its Acurate devices due to “increased clinical and regulatory requirements.”

MedTech Dive 5 days ago

BSX

MDT

JNJ
1 Top Dividend Stock to Buy for a Lifetime of Passive Income

The healthcare leader has a solid and diversified business that can overcome these headwinds. J&J has increased its dividend for 62 consecutive years. There are hundreds of dividend stocks on the market, but they don't all offer the same level of security.

Motley Fool 6 days ago

JNJ
US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson’s DARZALEX FASPRO

On May 20, Johnson & Johnson (NYSE:JNJ) announced that the FDA Oncologic Drugs Advisory Committee/ODAC voted 6-2 in favor of the benefit-risk profile of single-agent DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adult patients with high-risk smoldering multiple myeloma (HR-SMM). This recommendation is a step towards potentially making DARZALEX FASPRO the first treatment to delay […]

Insider Monkey 8 days ago

JNJ
Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond

Chevron has hiked its dividends for 38 straight years. Johnson & Johnson recently raised its dividend for the 63rd year in a row. Verizon has the longest dividend growth streak in the U.S. telecom sector.

Motley Fool 9 days ago

JNJ

CVX

VZ
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.51, denoting a -0.44% change from the preceding trading day.

Zacks 10 days ago

JNJ

^GSPC
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges

While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern

Zacks 11 days ago

JNJ
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

Zacks 11 days ago

CGON

JNJ
Johnson & Johnson MedTech introduces ultrasound catheter for cardiac ablation

Featuring an 88-element phased linear array, the catheter claims to deliver detailed visualisation.

Medical Device Network 11 days ago

JNJ
Johnson & Johnson (NYSE:JNJ) FDA Panel Supports DARZALEX FASPRO®? for High-Risk Multiple Myeloma

Johnson & Johnson (NYSE:JNJ) recently garnered attention when the FDA's Oncologic Drugs Advisory Committee voted favorably on the use of DARZALEX FASPRO® for high-risk smoldering multiple myeloma. This announcement comes amid a broad market environment where the S&P 500 has faced slight declines. The company’s shares increased 3.52% over the last week, possibly bolstered by these positive regulatory outcomes. As broader market factors weighed on indices, with the S&P 500 also navigating...

Simply Wall St. 12 days ago

JNJ
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks 12 days ago

JNJ
Johnson & Johnson's (NYSE:JNJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Johnson & Johnson ( NYSE:JNJ ) will increase its dividend from last year's comparable payment on the 10th of June to...

Simply Wall St. 12 days ago

JNJ
Johnson & Johnson (NYSE:JNJ) Hit with $147M Verdict in Landmark Antitrust Case Over Reprocessed Medical Devices

A federal jury in Santa Ana has ordered Johnson & Johnson (NYSE:JNJ) to pay $147 million after its Biosense Webster unit was found guilty of violating antitrust laws. The court ruled J&J illegally withheld clinical support from hospitals using FDA-approved reprocessed catheters, directly undermining competition in the single-use device (SUD) market. Plaintiff Innovative Health secured […]

Insider Monkey 12 days ago

JNJ
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). An application for the approval of DARZALEX FASPRO® for adult patients with HR-SMM was submitted to the FDA in November 2024.

PR Newswire 12 days ago

JNJ

Performance Overview

Return	JNJ.BE	S&P 500 (^GSPC)
YTD	-0.98%	+0.82%
1-Year	+3.93%	+12.36%
3-Year	-10.17%	+41.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Johnson & Johnson (JNJ.BE)

Johnson & Johnson (NYSE:JNJ) Unveils Promising Prostate Cancer Data With Pasritamig

ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug

COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?

HistoSonics’ histotripsy system receives early market access authorisation in UK

3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Row

Johnson & Johnson (JNJ) Stock Moves -0.54%: What You Should Know

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Boston Scientific ends TAVR sales; J&J shares Monarch robot data

1 Top Dividend Stock to Buy for a Lifetime of Passive Income

US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson’s DARZALEX FASPRO

Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond

Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

Johnson & Johnson MedTech introduces ultrasound catheter for cardiac ablation

Johnson & Johnson (NYSE:JNJ) FDA Panel Supports DARZALEX FASPRO®? for High-Risk Multiple Myeloma

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Johnson & Johnson's (NYSE:JNJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Johnson & Johnson (NYSE:JNJ) Hit with $147M Verdict in Landmark Antitrust Case Over Reprocessed Medical Devices

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

Performance Overview